VistaGen Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.311
- Today's High:
- $6.9763
- Open Price:
- $6.7
- 52W Low:
- $1.62
- 52W High:
- $13.05
- Prev. Close:
- $6.65
- Volume:
- 663068
Company Statistics
- Market Cap.:
- $62.26 million
- Book Value:
- 0.87
- Revenue TTM:
- $-359800
- Operating Margin TTM:
- 12921.82%
- Gross Profit TTM:
- $-227300
- Profit Margin:
- 0%
- Return on Assets TTM:
- -78.79%
- Return on Equity TTM:
- -175.33%
Company Profile
VistaGen Therapeutics Inc had its IPO on 2016-05-06 under the ticker symbol VTGN.
The company operates in the Healthcare sector and Biotechnology industry. VistaGen Therapeutics Inc has a staff strength of 32 employees.
Stock update
Shares of VistaGen Therapeutics Inc opened at $6.7 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.31 - $6.98, and closed at $6.48.
This is a -2.56% slip from the previous day's closing price.
A total volume of 663,068 shares were traded at the close of the day’s session.
In the last one week, shares of VistaGen Therapeutics Inc have increased by +9.46%.
VistaGen Therapeutics Inc's Key Ratios
VistaGen Therapeutics Inc has a market cap of $62.26 million, indicating a price to book ratio of 0.8384 and a price to sales ratio of 23.1523.
In the last 12-months VistaGen Therapeutics Inc’s revenue was $-359800 with a gross profit of $-227300 and an EBITDA of $-46364000. The EBITDA ratio measures VistaGen Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, VistaGen Therapeutics Inc’s operating margin was 12921.82% while its return on assets stood at -78.79% with a return of equity of -175.33%.
In Q2, VistaGen Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 42.7%.
VistaGen Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-6.8 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into VistaGen Therapeutics Inc’s profitability.
VistaGen Therapeutics Inc stock is trading at a EV to sales ratio of 44.9553 and a EV to EBITDA ratio of 0.1309. Its price to sales ratio in the trailing 12-months stood at 23.1523.
VistaGen Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $15.03 million
- Total Liabilities
- $4.05 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
VistaGen Therapeutics Inc ended 2024 with $15.03 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.03 million while shareholder equity stood at $6.85 million.
VistaGen Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.05 million in other current liabilities, 7900.00 in common stock, $-333754800.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.62 million and cash and short-term investments were $9.62 million. The company’s total short-term debt was $1,287,000 while long-term debt stood at $0.
VistaGen Therapeutics Inc’s total current assets stands at $11.58 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $659000.00 compared to accounts payable of $1.62 million and inventory worth $-591900.00.
In 2024, VistaGen Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, VistaGen Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.48
- 52-Week High
- $13.05
- 52-Week Low
- $1.62
- Analyst Target Price
- $30
VistaGen Therapeutics Inc stock is currently trading at $6.48 per share. It touched a 52-week high of $13.05 and a 52-week low of $13.05. Analysts tracking the stock have a 12-month average target price of $30.
Its 50-day moving average was $4.17 and 200-day moving average was $4.21 The short ratio stood at 0.29 indicating a short percent outstanding of 0%.
Around 78.8% of the company’s stock are held by insiders while 1143.8% are held by institutions.
Frequently Asked Questions About VistaGen Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.